A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

Completed · Phase 3

Conditions studied: Factor VIII Deficiency

In brief

Primary Objective: \- To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm. Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for the prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life outcomes. * To evaluate the efficacy of BIVV001 for perioperative management. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the pharmacokinetics (PK) of BIVV001 based on the 1-stage activated partial thromboplastin time (aPTT) and 2-stage chromogenic coagulation factor VIII (FVIII) activity assays.

Key facts

Study ID: NCT04161495
Run by: Bioverativ, a Sanofi company
People needed: 159
Starts: 2019-11-19
Expected to finish: 2022-02-03
Last updated by the study team: 2025-09-17

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participant, male or female, must be equal to or greater than 12 years of age inclusive, at the time of signing the informed consent.
Severe hemophilia A, defined as less than (<) 1 international units per deciliter (IU/dL) (<1 percent [%]) endogenous FVIII activity as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating <1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A.
Previous treatment for hemophilia A (prophylaxis or on demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days.
Current regimen included one of the following:
Prophylactic treatment regimen with a FVIII product or prophylactic emicizumab therapy for at least 6 months during the previous 12 months. Appropriate washout time needs to be taken into account.
On-demand regimen with a FVIII product with a history of at least 12 bleeding episodes in the previous 12 months or at least 6 bleeding episodes in the previous 6 months prior to study enrollment.
On-demand participant was accepted to move to a prophylaxis treatment regimen after 26-week on-demand period.
Willingness and ability of the participant or surrogate (a caregiver or a family member greater than or equal to [>=] 18 years of age) to complete training in the use of the study electronic Patient Diary (ePD) and to use the ePD throughout the study.
Ability of the participant or his or her legally authorized representative (eg., parent or legal guardian) to understand the purpose and risks of the study, willing and able to comply with study requirements and provide signed and dated informed consent or assent (as applicable) and authorization to use protected health information in accordance with national and local participant privacy regulations.

You may not qualify if…

Clinically significant liver disease.
Serious active bacterial or viral infection (other than chronic hepatitis or HIV) present within 30 days of screening.
Other known coagulation disorder(s) in addition to hemophilia A.
History of hypersensitivity or anaphylaxis associated with any FVIII product.
Positive inhibitor results, defined as >=0.6 Bethesda unit per milliliter (BU/mL) at screening. History of a positive inhibitor test defined as >=0.6 BU/mL. Family history of inhibitors would not exclude the participant.
Use of Emicizumab within the 20 weeks prior to screening.
Major surgery within 8 weeks prior to screening.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

Investigational Site Number 920 — Los Angeles, California, United States
Investigational Site Number 921 — Los Angeles, California, United States
Investigational Site Number 911 — San Diego, California, United States
Investigational Site Number 917 — Gainesville, Florida, United States
Investigational Site Number 919 — Ann Arbor, Michigan, United States
Investigational Site Number 908 — Lansing, Michigan, United States
Investigational Site Number 906 — Las Vegas, Nevada, United States
Investigational Site Number 902 — Seattle, Washington, United States
Investigational Site Number 136 — Buenos Aires, Argentina
Investigational Site Number 137 — Buenos Aires, Argentina
Investigational Site Number 139 — Mendoza, Argentina
Investigational Site Number 121 — Perth, Australia
Investigational Site Number 122 — Sydney, Australia
Investigational Site Number 161 — Brussels, Belgium
Investigational Site Number 181 — Campinas, Brazil
Investigational Site Number 171 — Plovdiv, Bulgaria
Investigational Site Number 172 — Sofia, Bulgaria
Investigational Site Number 202 — Hamilton, Canada
Investigational Site Number 205 — Hamilton, Canada
Investigational Site Number 281 — Brest, France
Investigational Site Number 283 — Lille, France
Investigational Site Number 282 — Lyon, France
Investigational Site Number 284 — Marseille, France
Investigational Site Number 304 — Berlin, Germany
Investigational Site Number 302 — Bonn, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.